REG - Venture Life Group - Investor Presentation via Investor Meet Company

Venture LifeAnnouncement

26/03/2026 09:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260326:nRSZ2690Ya&default-theme=true

RNS Number : 2690Y  Venture Life Group PLC  26 March 2026

26 March 2026

 

 

VENTURE LIFE GROUP PLC

 

("Venture Life", "VLG" or the "Group")

 

Investor Presentation via Investor Meet Company

 

Venture Life (AIM: VLG) is pleased to announce that Jerry Randall (CEO),
Daniel Wells (CFO) and Kate Bache (Chief Innovation & Marketing Officer)
will provide a live presentation relating to the Interim Results for the 12
month period ended 31 December 2025 via Investor Meet Company on 02 April
2026, 14:30 BST.

 

The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 01 April 2026, 09:00 BST, or at any time during
the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to
meet Venture Life Group plc via:

 

https://www.investormeetcompany.com/venture-life-group-plc/register-investor
(https://url.uk.m.mimecastprotect.com/s/Da0cCvYArhG5zkCQfptQO9ln?domain=investormeetcompany.com)

 

Investors who already follow Venture Life Group plc on the Investor Meet
Company platform will automatically be invited.

 

 

For further information, please contact:

 

Venture Life Group
PLC
                +44 (0) 1344 578004

 

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and
Broker)
           +44 (0) 20 7720 0500

 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

 

Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in
the UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health & Her product range supporting the hormonal lifecycle.

 

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK,  Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKQLBLQXLXBBF



            Copyright 2019 Regulatory News Service, all rights reserved